Remove 2024 Remove Contracts Remove Marketing Remove Settlement
article thumbnail

adult venue's insurer did not successfully exclude ads from ad injury coverage

43(B)log

2024 WL 1285631, C.A. 26, 2024) Defendant, d/b/a Wonderland, operated an adult entertainment club and was one of the many such sued by various models for using their images in advertising without their consent from 2015 to 2019. Defendants counterclaimed for payment and damages for breach of contract and bad faith.

article thumbnail

FTC Prohibits X-Mode Social/Outlogic from Selling Sensitive Location Data

LexBlog IP

” The FTC’s settlement with X-Mode/Outlogic marks its first with a “data broker concerning the collection and sale of sensitive location information.” ” The FTC’s settlement with X-Mode/Outlogic marks its first with a “data broker concerning the collection and sale of sensitive location information.”

Privacy 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is the NLRB’s New Stance on Restrictive Covenants Mostly Bark With a Little Bite?

Trading Secrets

In response, the company filed a lawsuit against the now-former employee, alleging breach of contract, breach of fiduciary duty, and misappropriation of trade secrets. And, perhaps most notably, the Division implicitly found that one invalid provision in a contract does not invalidate the entire contract.

article thumbnail

Is the NLRB’s New Stance on Restrictive Covenants Mostly Bark With a Little Bite?

LexBlog IP

In response, the company filed a lawsuit against the now-former employee, alleging breach of contract, breach of fiduciary duty, and misappropriation of trade secrets. And, perhaps most notably, the Division implicitly found that one invalid provision in a contract does not invalidate the entire contract.

article thumbnail

Year in Review: Top Legal Developments of 2023

LexBlog IP

As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. That IPR was terminated in August in view of a settlement agreement and before there was any decision on institution. That case is ongoing with a jury trial set for November 2024.

article thumbnail

The First Precedential Patent Decision of 2023: Dexcom v. Abbott Diabetes Care

Patently-O

January 3, 2024). The patentee had requested an order barring Abbott from pursuing its IPR challenges – based upon a forum selection clause that was part of a prior settlement between the parties. Background of the Dispute DexCom and Abbott are competitors in the continuous glucose monitoring systems market. DexCom at 9.

Patent 63
article thumbnail

where cross-examination exposes lack of TM confusion, out-of-court confusion "evidence" becomes less credible

43(B)log

2024 WL 22039, No: 6:20-cv-2354-GAP-EJK (M.D. 2, 2024) Some interesting comments on when individual instances of “confusion” don’t count, as well as their relevance to evaluating out-of-court social media etc. And they targeted school districts in their marketing. Defendants market only their K12 brand nationally.